Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

A-903

Supelco

Alprazolam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C17H13ClN4
Número de CAS:
28981-97-7
Peso molecular:
308.76
Número CE:
200-659-6
Número MDL:
MFCD00078881
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329771027
NACRES:
NA.24

grado

certified reference material

Nivel de calidad

300

formulario

liquid

Características

SNAP-N-SPIKE®, SNAP-N-SHOOT®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

concentración

1.0 mg/mL in methanol

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

formato

single component solution

temp. de almacenamiento

−20°C

cadena SMILES

Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4-n12

InChI

1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3

Clave InChI

VREFGVBLTWBCJP-UHFFFAOYSA-N

Información sobre el gen

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Alprazolam is a benzodiazepine drug used for the medical treatment of anxiety and panic disorders, including generalized or social anxiety disorder. This certified reference standard is suitable for use in a wide variety of LC/MS or GC/MS testing applications from forensic analysis and clinical toxicology to urine drug testing and pain prescription monitoring. Alprazolam is sold under the trade name Xanax®.

Aplicación


  • Alprazolam Solid Lipid Nanoparticles for Sustained Release: This study explores the development of Compritol-based Alprazolam solid lipid nanoparticles, demonstrating a novel approach for sustained release formulations in benzodiazepine biochemistry. The technique is critical for improving the pharmacokinetics of anxiolytic compounds, ensuring controlled release and enhanced bioavailability (Rao et al., 2022).

  • Extraction of Alprazolam in Biological Samples: Application of dispersive solid-phase extraction using nanographene oxide grafted with α-pyridylamine for alprazolam, which is significant for forensic and clinical toxicology. This method enhances the precision of benzodiazepine detection in complex biological matrices, pivotal for neuropharmacological studies (Parsayi Arvand et al., 2023).

  • Raman Spectroscopy in Drug Abuse Analysis: Utilization of portable Raman spectroscopy for the detection of drugs of abuse, including Alprazolam. This research underscores the importance of Alprazolam research solutions in developing rapid and non-destructive testing methods, contributing to advancements in forensic science (Santos et al., 2022).

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Xanax is a registered trademark of Pharmacia & Upjohn Company

Producto relacionado

Referencia del producto
Descripción
Precios

A-902

Alprazolam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-904

alpha-Hydroxyalprazolam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-907

alpha-Hydroxyalprazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-908

alpha-Hydroxyalprazolam-d5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-910

Alprazolam-d5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

IMF-020S

iMethod Test Kit for Benzodiazepines with Synthetic Urine, kit of 23 × 1.0 mL ampules, certified reference material, Cerilliant®

H-142

4-Hydroxyalprazolam solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

H-143

4-Hydroxyalprazolam-D5 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

F-095

Flualprazolam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

F-096

Flualprazolam-D4 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-108

Bromazolam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órganos de actuación

Eyes,Central nervous system

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Dean T Acheson et al.
Human psychopharmacology, 27(4), 419-427 (2012-07-12)
Heightened anticipation of future events has been characterized as a feature of certain anxiety disorders. In functional magnetic resonance imaging studies, anticipation of fearful/threatening images has been shown to robustly activate the insular cortex and amygdala in healthy subjects, in
J M Jonas et al.
The Journal of clinical psychiatry, 54 Suppl, 25-45 (1993-10-01)
A review of the worldwide published literature was conducted to assess the efficacy and safety of alprazolam for the treatment of anxiety disorders, panic disorder, and depression in comparison with those of other active drugs (including other benzodiazepines and antidepressant
E M Sellers et al.
The Journal of clinical psychiatry, 54 Suppl, 64-75 (1993-10-01)
The incidence of nonmedical use of alprazolam is very low relative to its widespread legitimate medical use; in fact, given the millions of patients who have received this medication, the incidence is remarkably small. In particular, among patients with anxiety
J O Cole et al.
The Journal of clinical psychiatry, 54 Suppl, 49-61 (1993-10-01)
A review of the published case reports of adverse behavioral episodes or unexpected psychopathology in patients taking benzodiazepines was undertaken in an attempt to determine if these adverse or unexpected events are more likely to occur with alprazolam when compared
Steven Moylan et al.
The Australian and New Zealand journal of psychiatry, 46(3), 212-224 (2012-03-07)
To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature. Data were sourced by a literature search using MEDLINE, Embase
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico